Free Trial
NASDAQ:COLL

Collegium Pharmaceutical (COLL) Stock Price, News & Analysis

Collegium Pharmaceutical logo
$32.52 -0.48 (-1.45%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$32.49 -0.03 (-0.08%)
As of 07/11/2025 04:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Collegium Pharmaceutical Stock (NASDAQ:COLL)

Key Stats

Today's Range
$32.45
$33.01
50-Day Range
$27.03
$33.00
52-Week Range
$23.23
$42.29
Volume
189,895 shs
Average Volume
400,001 shs
Market Capitalization
$1.04 billion
P/E Ratio
26.66
Dividend Yield
N/A
Price Target
$43.75
Consensus Rating
Moderate Buy

Company Overview

Collegium Pharmaceutical Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
84th Percentile Overall Score

COLL MarketRank™: 

Collegium Pharmaceutical scored higher than 84% of companies evaluated by MarketBeat, and ranked 149th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Collegium Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Collegium Pharmaceutical has only been the subject of 1 research reports in the past 90 days.

  • Read more about Collegium Pharmaceutical's stock forecast and price target.
  • Earnings Growth

    Earnings for Collegium Pharmaceutical are expected to grow by 7.12% in the coming year, from $5.62 to $6.02 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Collegium Pharmaceutical is 26.66, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.85.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Collegium Pharmaceutical is 26.66, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.26.

  • Price to Book Value per Share Ratio

    Collegium Pharmaceutical has a P/B Ratio of 4.58. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Collegium Pharmaceutical's valuation and earnings.
  • Percentage of Shares Shorted

    14.13% of the float of Collegium Pharmaceutical has been sold short.
  • Short Interest Ratio / Days to Cover

    Collegium Pharmaceutical has a short interest ratio ("days to cover") of 13.3, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Collegium Pharmaceutical has recently decreased by 9.75%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Collegium Pharmaceutical does not currently pay a dividend.

  • Dividend Growth

    Collegium Pharmaceutical does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    14.13% of the float of Collegium Pharmaceutical has been sold short.
  • Short Interest Ratio / Days to Cover

    Collegium Pharmaceutical has a short interest ratio ("days to cover") of 13.3, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Collegium Pharmaceutical has recently decreased by 9.75%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Collegium Pharmaceutical has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 12 news articles for Collegium Pharmaceutical this week, compared to 5 articles on an average week.
  • Search Interest

    4 people have searched for COLL on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.
  • MarketBeat Follows

    4 people have added Collegium Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Collegium Pharmaceutical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $202,123.00 in company stock.

  • Percentage Held by Insiders

    Only 2.51% of the stock of Collegium Pharmaceutical is held by insiders.

  • Read more about Collegium Pharmaceutical's insider trading history.
Receive COLL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Collegium Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

COLL Stock News Headlines

Stock Buybacks spark investor interest - This image is an original composition by MarketBeat using licensed and editorial elements. Not for redistribution or reuse.
5 Hot Stocks With Summer Buybacks You Can Cash In On (COLL)
The five stocks on this list issued aggressive buyback authorizations in June or July and have the power to follow through with their plans.
Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.
See More Headlines

COLL Stock Analysis - Frequently Asked Questions

Collegium Pharmaceutical's stock was trading at $28.65 at the beginning of 2025. Since then, COLL shares have increased by 13.5% and is now trading at $32.52.

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) issued its quarterly earnings results on Thursday, May, 8th. The specialty pharmaceutical company reported $1.49 EPS for the quarter, missing analysts' consensus estimates of $1.50 by $0.01. The firm's revenue was up 22.7% compared to the same quarter last year.
Read the conference call transcript
.

Collegium Pharmaceutical's board initiated a stock buyback program on Monday, July 7th 2025, which authorizes the company to buy back $150,000,000 in shares, according to EventVestor. This means that the company could repurchase up to 15.4% of its stock through open market purchases. Stock buyback programs are generally a sign that the company's leadership believes its shares are undervalued.

Collegium Pharmaceutical (COLL) raised $75 million in an initial public offering on Thursday, May 7th 2015. The company issued 5,800,000 shares at a price of $12.00-$14.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers.

Top institutional shareholders of Collegium Pharmaceutical include Exchange Traded Concepts LLC (0.20%), Harbor Capital Advisors Inc. (0.06%) and Farther Finance Advisors LLC (0.04%). Insiders that own company stock include Joseph Ciaffoni, Colleen Tupper, Scott Dreyer, Shirley R Kuhlmann, John Gordon Freund, Thomas B Smith, Garen G Bohlin and Michael Thomas Heffernan.
View institutional ownership trends
.

Shares of COLL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Collegium Pharmaceutical investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Arista Networks (ANET), Netflix (NFLX) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
5/08/2025
Today
7/13/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:COLL
CIK
1267565
Fax
N/A
Employees
210
Year Founded
N/A

Price Target and Rating

High Price Target
$50.00
Low Price Target
$37.00
Potential Upside/Downside
+34.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
$1.22
Trailing P/E Ratio
26.66
Forward P/E Ratio
5.79
P/E Growth
N/A
Net Income
$69.19 million
Net Margins
6.61%
Pretax Margin
9.80%
Return on Equity
99.08%
Return on Assets
15.14%

Debt

Debt-to-Equity Ratio
3.30
Current Ratio
1.08
Quick Ratio
1.01

Sales & Book Value

Annual Sales
$664.28 million
Price / Sales
1.57
Cash Flow
$12.37 per share
Price / Cash Flow
2.63
Book Value
$7.10 per share
Price / Book
4.58

Miscellaneous

Outstanding Shares
32,132,000
Free Float
31,325,000
Market Cap
$1.04 billion
Optionable
Optionable
Beta
0.64

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:COLL) was last updated on 7/13/2025 by MarketBeat.com Staff
From Our Partners